Atorvastatin prevents dehydromonocrotaline-induced pulmonary hypertension in beagles

Experimental Lung Research

Volumn 38, Issue 7, 2012, Pages 333-343

  Chen, Dandan ^a   Zhou, Daxin ^a   Qian, Juying ^a   Chen, Fadong ^a   Guan, Lihua ^a   Dong, Lili ^a   Ge, Junbo ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Hypertension pulmonary; Mechanism; Pulmonary vascular endothelial; Statin

Indexed keywords

ATORVASTATIN; EOSIN; HEMATOXYLIN; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCROTALINE PYRROLE; SIMVASTATIN; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DOG; EXPERIMENTAL ANIMAL; FEMALE; HEMODYNAMICS; LUNG ARTERY PRESSURE; LUNG INJURY; LUNG PARENCHYMA; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; STAINING; THERMODILUTION;

ALKYLATING AGENTS; ANIMALS; CELL PROLIFERATION; CYTOKINES; DOGS; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; LUNG; MALE; MONOCROTALINE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE TYPE III; PYRROLES;

EID: 84865132320     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2012.702852     Document Type: Article

References (59)

1. Fishman AP, Fishman MC, Freeman BA,Gimbrone MA, Rabinovitch M, Robinson D, Gail DB: Mechanisms of proliferative and obliterative vascular diseases: insights from the pulmonary and systemic circulations. NHLBI Workshop Summary. Am J Respir Crit Care Med. 1998;158:670-674. (Pubitemid 28378201)
2. Galie N, Manes A, Farahani KV, Pelino F, Palazzini M, Negro L, Romanazzi S, Branzi A: Pulmonary arterial hypertension associated to connective tissue diseases. Lupus. 2005;14(9):713-717. (Pubitemid 41413297)
3. McLaughin VV, HoeperMM:Pulmonary arterial hypertension: the race for the most effective treatment. Am J Respir Crit Care Med. 2005;171:1199-1201. (Pubitemid 40740725)
4. Runo JR, Loyd JE: Primary pulmonary hypertension. Lancet. 2003;361(9368):1533-1544. (Pubitemid 36566349)
5. Kinlay S: Potential vascular benefits of statins. Am J Med. 2005;118(Suppl):62-67.
6. Koh KK: Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000;47:648-657.
7. Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, Lirussi F, Bardou M: The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn-Schmiedeberg's Arch Pharmacol. 2006;373(6):401-414. (Pubitemid 44401411)
8. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao PN: Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit CareMed. 2002;166:1403-1408. (Pubitemid 35292709)
9. Nishimura T, Vaszar LT, Faul JL, Zhao GH, Berry GJ, Shi LF, Qiu DM, Benson G, Pearl RG, Kao PN: Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation. 2003;108:1640-1645. (Pubitemid 37187793)
10. Girgis RE, Li D, Zhan X, Garcia JGN, Tuder RM, Hassoun PM, Johns RA: Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol. 2003;285:938-945.
11. Laufs U, Marra D, Node K, Liao JK: 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27Kip1. J Biol Chem. 1999;274(31):21926-21931.
12. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani A, Leccia A, Cavuto L, Stingone AM, Chieffo A, Capozzolo C, Chiariello M: Effects of hydroxymethylglutaryl coenzyme a reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol. 2000;35(1): 214-221. (Pubitemid 30061283)
13. Satoh K, Ichihara K, Landon EJ, Inagami T, Tang H: 3-Hydroxy-3- methylglutaryl-CoA reductase inhibitors block calcium-dependent tyrosine kinase Pyk2 activation by angiotensin II in vascular endothelial cells: involvement of geranylgeranylation of small G protein Rap1. J Biol Chem. 2001;276:15761-15767.
14. Laufs U, Fata VL, Liao JK: Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxiamediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997;272:31725-31729. (Pubitemid 28013321)
15. Wei-hua Zhang, Yun-jian Zhang, Chun-ping Liu, Bing-xiang Yu, Wei-xuan Lu: Simvastatin protects against the development of monocrotaline-induced pulmonary hypertension in rats via a heme oxygenase-1-dependent pathway. Exp Lung Res. 2011;37:492-499.
16. Wilkins MR, Ali O, Bradlow W, Wharton J, Taegtmeyer A, Rhodes CJ, Ghofrani HA, Howard L, Nihoyannopoulos P, Mohiaddin RH, Gibbs JS: Simvastatin as a treatment for pulmonary hypertension trial. Am J of Respir Crit Care. 2010;181:1106-1113.
17. Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, Lameire NH: Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant. 2003;18:967-976. (Pubitemid 36592541)
18. Mattocks AR, Rebekah J, Janet B: Simple procedures for preparing putative toxic metabolites of pyrrolizidine alkaloids. Toxicon. 1989;27(5):561-567. (Pubitemid 19121751)
19. Tang J, Wang ZT, Zhang M, Teruaki A, Norio N, Masao H: Release and identification of monocrotaline acid from dehydromonocrotaline. J Chin Pharma Univer. 2003;34(6):499-502. (Pubitemid 43026908)
20. Okada M, Yamashita C, Okada M, Okada K: A dehydromonocrotaline-induced pulmonary hypertension model in the beagle. J Thorac Cardiovasc Surg. 1995;110:546-547.
21. Pan LC, Wilson DW, Lame MW, Jones AD, Segall HJ: COR pulmonale is caused by monocrotaline and dehydromonocrotaline, but not by glutathione or cysteine conjugates of dihydropyrrolizine, Toxicol Appl Pharmacol. 1993;118(1):87-97. (Pubitemid 23069440)
22. Reindel JF, Ganey PE, Wagner JG, Slocombe RF, Roth RA: Development of morphologic,hemodynamic, and biochemical changes in lungs of rats given monocrotaline pyrrole. Toxicol Appl Pharmacol. 1990;106(2):179-200.
23. Rothman A, Wiencek RG, Davidson S, Evans WN, Restrepo H, Sarukhanov V, Rivera-Begeman A, Mann D: Hemodynamic and histologic characterization of a swine (Sus scrofa domestica) model of chronic pulmonary arterial hypertension. Comp Med. 2011;61:258-262.
24. Chin KM, Kim MH, Rubin, LJ: The right ventricle in pulmonary hypertension. Coron Artery Dis. 2005;16:13-18. (Pubitemid 40279592)
25. Carlos AC, Junior D, GladwinMT, Tanus-Santos JE: Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. Free Radical Biol. Med. 2006;41:1764-1770.
26. Dumitrascu R, Koebrich S, Dony E, Weissmann N, Savai R, Pullamsetti SS, Ghofrani HA, Samidurai A, Traupe H, Seeger W, Grimminger F, Schermuly RT: Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. BMC Pulm Med. 2008;8:25
27. Wang W, Zhang YD, Shu MW: A model of hyperkinetic pulmonary hypertension in rabbits. Chin J pathol. 2006;22:612-615.
28. Humbert M, Nunes H, Sitbon O, Parent F, Herv́e P, Simonneau G: Risk factors for pulmonary arterial hypertension. Clin Chest Med. 2001;22(3):459-475. (Pubitemid 32912079)
29. Isern RA, Yaneva M,Weiner E, Parke A, Rothfield N, Dantzker D, Rich S, Arnett FC: Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. Am J Med. 1992;93(3):307-312.
30. HumbertM,Monti G, Brenot F, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D: Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;151(5):1628-1631.
31. HumbertM,Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, Capron F, Galanaud P, Duroux P, Simonneau G, Emilie D: Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J. 1998;11(3):554-559. (Pubitemid 28194842)
32. Fartoukh M, Emilie D, Le Gall C, Monti G, Simonneau G, HumbertM: Chemokine MIP-1a expression in lung biopsies of primary pulmonary hypertension. Chest. 1998;114:S50-S51.
33. Tuder RM, Groves B, Badesch DB, Voelkel NF: Exuberant endothelial cell growth and element of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144(2):275-285. (Pubitemid 24165948)
34. Voelkel NF, Tuder RM, Bridges J, Arend WP: Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol. 1994;11(6):664-675.
35. Kimura H, Kasahara Y, Kurosu K, Sugito K, Takiguchi Y, Terai M, Mikata A, Natsume M, Mukaida N, Matsushima K, Kuriyama T: Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest. 1998;78(5):571-581. (Pubitemid 28246981)
36. Joppa P, Petrasova D, Stancak B, Tkacova R: Systemic inflammation in patients with COPD and pulmonary hypertension. CHEST. 2006;130:326-333. (Pubitemid 44266997)
37. Nelson S, Bagby GJ, Bainton BG, Wilson LA, Thompson JJ, Summer WR: Compartmentalization of intra alveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis. 1989;159(2):189-194. (Pubitemid 19049356)
38. Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717-1725. (Pubitemid 26193625)
39. Fujita M, Shannon JM, Irvin CG, Fagan KA, Cool C, Augustin A, Mason RJ: Overexpression of tumor necrosis factor-αproduces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2001;280(1):39-49.
40. Ortiz LA, Lasky J, Hamilton RF, Holian A, Hoyle GW, Banks W, Peschon JJ, Brody AR, Lungarella G, Friedman M: Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res. 1998;24(6):721-743. (Pubitemid 28533206)
41. Langer F, Schramm R, Bauer M, Tscholl D, Kunihara T, Schafers HJ: Cytokine response to pulmonary thromboendarterectomy. Chest. 2004;126:135-141. (Pubitemid 38943129)
42. Kimura H, Okada O, Tanabe N, Tanaka Y, Terai M, Takiguchi Y, Masuda M, Nakajima N, Hiroshima K, Inadera H, Matsushima K, Kuriyama T: Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2001;164:319-324. (Pubitemid 34001302)
43. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306-1309. (Pubitemid 20066716)
44. Zaiman AL, Tuder RM: Hypoxia-sensitive transcription factors and growth factors. In: Yuan JXJ, ed. Hypoxic Pulmonary Vasoconstriction. Norwell, MA: Kluwer Academic; 2004:437-447.
45. Geiger R, Berger RM, Hess J, Bogers AJ, Sharma HS, Mooi WJ: Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease. J Pathol. 2000;191(2):202-207. (Pubitemid 30394900)
46. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, Yacoub M, Polak JM, Voelkel NF: Expression of angiogenesisrelated molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol. 2001;195(3):367-374.
47. Partovian C, Adnot S, Eddahibi S, Teiger E, Levame M, Dreyfus P, Raffestin B, Frelin C: Heart and lung VEGF mRNA expression in rats with monocrotaline-or hypoxia-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol. 1998;275(6):1948-1956.
48. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, Selwyn AP: Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 1997;95:324-328. (Pubitemid 27056194)
49. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci. 1998;95(15):8880-8885. (Pubitemid 28350583)
50. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA: Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001;32:980-986.
51. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMGcoenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126-1131. (Pubitemid 27097821)
52. Giaid A, Saleh D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214-221.
53. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent: vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;322(31):441-415.
54. Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA: Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling. Am J Respir Cell Mol Biol. 2001;25(1):104-110. (Pubitemid 32682712)
55. Barreto AC, MaedaNY, Soares RP, Cicero C, Lopes AA: Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension. Braz J Med Biol Res. 2008;41:657-663.
56. Kawut SM, Bagiella E, Lederer DJ, Shimbo D, Horn EM, Roberts KE, Hill NS, Barr RG, Rosenzweig EB, Post W, Tracy RP, Palevsky HI, Hassoun PM, Girgis RE: BCh on behalf of the ASA-STAT study group, randomized clinical trial of Aspirin and Simvastatin for pulmonary arterial hypertension ASASTAT. Circulation. 2011;123:2985-2993.
57. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, Michelakis ED: Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004;95:830-840. (Pubitemid 39390586)
58. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F: Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811-2821. (Pubitemid 41434408)
59. McMurtry MS, Bonnet S, Michelakis ED, Bonnet S, Haromy A, Archer SL: Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Lung Physiol. 2007;293(4):933-940.